Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,304 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Hematopoietic Malignancy Clear all

Completed Phase 2 Interventional Results available

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00941720

View directory record Official record

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Source: ClinicalTrials.gov public record

Updated Jul 23, 2020 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923

View directory record Official record

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: fenretinide; Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years to 120 Years

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 18, 2017 · Synced May 22, 2026, 5:29 AM EDT

Recruiting Not applicable Interventional Accepts healthy volunteers

Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study

NCT05772130

View directory record Official record

Conditions: Hematopoietic and Lymphoid System Neoplasm, Hereditary Malignant Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Electronic Health Record Review, Personal Contact, Survey Administration; Other · Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Duarte, California

Source: ClinicalTrials.gov public record

Updated Jan 4, 2026 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 2 Interventional

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

NCT00004061

View directory record Official record

Conditions: Leukemia, Lymphoma, Oral Complications
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years

Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Jun 25, 2013 · Synced May 22, 2026, 5:29 AM EDT

Withdrawn Phase 2 Interventional

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

NCT02682953

View directory record Official record

Conditions: Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
Interventions: Neupogen, Hyperbaric oxygen therapy, Plerixafor; Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Dec 10, 2019 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 2 Interventional Results available

Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia

NCT02807883

View directory record Official record

Conditions: Acute Lymphoblastic Leukemia
Interventions: Blinatumomab, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 70 Years

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 19, 2023 · Synced May 22, 2026, 5:29 AM EDT

Terminated Phase 1 Interventional

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

NCT04679194

View directory record Official record

Conditions: AML/MDS
Interventions: Mana 312; Biological
Lead sponsor: Mana Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Denver, Colorado • Atlanta, Georgia • Kansas City, Kansas + 4 more

Source: ClinicalTrials.gov public record

Updated Jun 17, 2023 · Synced May 22, 2026, 5:29 AM EDT

Terminated Not applicable Interventional Accepts healthy volunteers

Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE

NCT05012124

View directory record Official record

Conditions: Depression, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Collaborative care, Interview or Focus Group, Media/technology Intervention with collaborative care, Survey Administration; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older

Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Auburn, Washington • Gig Harbor, Washington • Seattle, Washington + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 15, 2026 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 2 Interventional Results available

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

NCT00782379

View directory record Official record

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: busulfan, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 60 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Source: ClinicalTrials.gov public record

Updated Nov 20, 2013 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 2 Interventional

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00003269

View directory record Official record

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide; Biological · Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 70 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: La Jolla, California

Source: ClinicalTrials.gov public record

Updated Jan 9, 2011 · Synced May 22, 2026, 5:29 AM EDT

Recruiting Not applicable Interventional Accepts healthy volunteers

Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial

NCT06314672

View directory record Official record

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Accrual, Discussion, Educational Activity, Interview, Review, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Not listed

Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Jun 28, 2025 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

NCT00003662

View directory record Official record

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Not listed

Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 15
States / cities: Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more

Source: ClinicalTrials.gov public record

Updated Mar 6, 2011 · Synced May 22, 2026, 5:29 AM EDT

Completed Not applicable Interventional

Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients

NCT00082654

View directory record Official record

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions: psychosocial assessment and care; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 21 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Sep 20, 2010 · Synced May 22, 2026, 5:29 AM EDT

Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

NCT04453072

View directory record Official record

Conditions: Obesity, Malignant Neoplasm
Interventions: Interview, Media Intervention, Questionnaire Administration, Scale Device, Telephone-Based Intervention, Text Message; Other · Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 13 Years to 30 Years

Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Source: ClinicalTrials.gov public record

Updated May 10, 2026 · Synced May 22, 2026, 5:29 AM EDT

Completed Not applicable Interventional Results available

Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors

NCT03967379

View directory record Official record

Conditions: Other Cancer
Interventions: Mobile App + enhanced standard care, Enhanced Standard Care; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Feb 3, 2025 · Synced May 22, 2026, 5:29 AM EDT

Enrolling by invitation No phase listed Observational

Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

NCT07594496

View directory record Official record

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older

Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Scottsdale, Arizona

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 5:29 AM EDT

Active, not recruiting Phase 2 Interventional Results available

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888

View directory record Official record

Conditions: Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 172
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 22, 2026, 5:29 AM EDT

Recruiting Phase 1 Interventional

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

NCT05443425

View directory record Official record

Conditions: Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions: Cholestyramine, Leflunomide, Steroid Therapy; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Source: ClinicalTrials.gov public record

Updated Jul 3, 2025 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 3 Interventional Results available

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515

View directory record Official record

Conditions: Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Months to 20 Years

Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 46
States / cities: Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more

Source: ClinicalTrials.gov public record

Updated Oct 15, 2024 · Synced May 22, 2026, 5:29 AM EDT

Recruiting No phase listed Observational

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

NCT01608152

View directory record Official record

Conditions: Leukemia, Lymphoma
Interventions: Focus Group, Internet-Based Intervention, Interview; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 39 Years

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Oct 26, 2025 · Synced May 22, 2026, 5:29 AM EDT

Recruiting Phase 2 Interventional

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

NCT07148947

View directory record Official record

Conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Interventions: Pacritinib, Decitabine, Decitabine and Cedazuridine, Azacitidine, Survey Administration, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Mar 3, 2026 · Synced May 22, 2026, 5:29 AM EDT

Completed Not applicable Interventional Results available

Symptom Management for YA Cancer Survivors

NCT04035447

View directory record Official record

Conditions: Cancer, Young Adult, Pain, Psychological Distress, Fatigue, Breast Cancer, Melanoma, Hematologic Cancer, Germ Cell Tumor, Endocrine Cancer
Interventions: Behavioral Symptom Management for Young Adult Cancer Survivors; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 39 Years

Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Source: ClinicalTrials.gov public record

Updated Jun 28, 2025 · Synced May 22, 2026, 5:29 AM EDT

Recruiting Phase 2 Interventional

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

NCT07336238

View directory record Official record

Conditions: Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Psychotherapy, Psilocybin, Survey Administration; Behavioral · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Apr 16, 2026 · Synced May 22, 2026, 5:29 AM EDT

Completed Phase 2 Interventional Results available

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

NCT01789255

View directory record Official record

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Graft Versus Host Disease, Intraocular Lymphoma, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Chronic Lymphocytic Leukemia, Refractory Cytopenia With Multilineage Dysplasia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Central Nervous System Hodgkin Lymphoma, Secondary Central Nervous System Non-Hodgkin Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions: vorinostat, tacrolimus, cyclosporine, methotrexate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years

Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Source: ClinicalTrials.gov public record

Updated Jul 23, 2018 · Synced May 22, 2026, 5:29 AM EDT